TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. - Wikidata - awgldk - TriplyDB

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

http://www.wikidata.org/entity/Q34508696

about

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer The genomic complexity of primary human prostate cancer Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets The role of SPINK1 in ETS rearrangement-negative prostate cancers Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer Recurrent rearrangements in prostate cancer: causes and therapeutic potential Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue Emerging critical role of molecular testing in diagnostic genitourinary pathology FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.Role of the TMPRSS2-ERG gene fusion in prostate cancer Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.Prognostic outlier genes for enhanced prostate cancer treatment.Allosteric Autoinhibition Pathway in Transcription Factor ERG: Dynamics Network and Mutant Experimental Evaluations.Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression.Integrative molecular concept modeling of prostate cancer progression.Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5.The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation.Mouse models of prostate cancer: picking the best model for the question.Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene New strategies in prostate cancer: translating genomics into the clinic Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study Molecular pathways: targeting ETS gene fusions in cancer.Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.Molecular pathways and targets in prostate cancer

P2860

Q24302687-09403A35-6FB6-4476-AAA7-AA64214236A2 Q24617949-486EBAA8-FDEE-4520-8A18-469F45BF12B3 Q24629083-BE36355E-2707-4497-A090-AEA7242C0648 Q24647020-19CF2232-0059-4DC9-B290-D66D2BD2C11B Q24650647-211DD0A4-70BC-41F6-99E7-5CC1C11F5906 Q24669875-DA3F345E-286B-48F8-977E-096586A9FD39 Q24676201-999BE2D3-FBF5-45C1-BFAD-F279FC746B7F Q24678489-37DF8915-92A2-43E0-A464-D42763408D28 Q26752933-994E738B-0A9D-478B-816D-04328F018977 Q26851525-49271F06-DCD6-4AEA-9269-4145661C7029 Q26997884-C89BCA20-70A5-45A2-A76E-13D7A773FBA7 Q27021371-AB06947A-EAAD-4F90-B5BC-8990DBB78DBB Q27851411-AD608BCF-A0FC-4A56-AAC7-31DAA7B68D3E Q27853114-5E0EE626-2CDE-4BE9-A971-8503F03FE84B Q28269156-2B399410-BAA9-4DF6-A055-244CC5A71B6F Q28469179-573BA085-7653-432D-8BE9-3098D6B853BD Q28472991-B6156D71-6BF3-41D4-B688-4CA0B7F6ECC6 Q28480861-82B3A29D-3C51-481A-A770-1DC83D0DB365 Q30008747-5386E12B-5862-4DA9-8525-6CFEC9A713EC Q30244674-B8A2421A-D2CF-435C-BEDA-06CAFF8CEF5F Q30401225-D26AFDEB-F055-44CD-A68E-0D4025DC5FB8 Q30414829-ADCCBCEC-7EE6-44DA-B254-FEFE63FA6FB5 Q30479181-343CFE43-0FDF-4B90-B933-23418791DD12 Q31005436-90492AAE-BE94-4FAE-9354-011C95D8456F Q31130674-B1B69AF3-102C-463F-B50F-BEBF38BC08D7 Q33266777-2F202981-4BC4-49FF-ADCE-7F6FE0B42BEE Q33359279-5E4C5432-0018-4B58-BD66-371BED999954 Q33375063-F6B5703A-D8CE-468C-8DBE-B7B3CC2452F5 Q33558203-C5AD7388-8DC4-4555-99BE-A49748BAEC39 Q33698635-276D0276-493B-433D-8868-2F54E806319C Q33772417-B2E6DD21-9355-4557-98CF-872DC98A8EC5 Q33813603-3499EAC4-78CE-4084-B183-2D911FB1AEAF Q33940867-15B8E8B0-3DED-4093-A115-78AE9CA6B0BE Q33952306-C4965FBD-8B4C-4063-91DC-1A980BAE19B2 Q33981506-0F69F58F-AE34-4DA0-B4DF-7FDB1E5D0C6E Q34007943-5C6CE7D5-E825-41CF-851A-33E50EA07065 Q34084882-67EE603A-F284-43AB-8A88-A95D3E2A0182 Q34135434-4EB97951-05D9-4EE7-B626-CF6010CC7F19 Q34158217-184E53D5-3AEA-4F2A-93DC-92A52CB84089 Q34365632-424D5B9E-C1E8-4155-995D-30570199EA7E

P2860

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

http://www.wikidata.org/entity/Q34508696

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@ast

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@en

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@nl

type

label

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@ast

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@en

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@nl

prefLabel

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@ast

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@en

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@nl

P1433

Q34508696-98F89768-2531-43CF-9222-71358CDBF659

P1476

Q34508696-A343749D-FEF9-418B-A100-A9703FB4D56E

P2093

Q34508696-087A12C4-BDFE-47E5-B45F-E8E91F580C9C

Q34508696-44496A07-D895-47F9-A472-61A7B489F0BA

Q34508696-45193D5C-524A-49AC-A206-2225B25A081F

Q34508696-739B746F-696E-455D-B752-FB2648FD76D9

Q34508696-82C4B7B4-04A3-494A-AAB9-54B0B060DACB

Q34508696-957A8F28-0554-48BC-BD52-1E76EF9344D4

Q34508696-974593A9-802F-462C-B905-4C1D02A79538

Q34508696-A9E5E22F-74D6-45BB-88E9-76E142407034

Q34508696-B0812A35-EC72-4C3D-933C-D6CDA5DAF91E

Q34508696-B0BAA940-E939-490F-B27E-7E3F027A3D8B

P304

Q34508696-F148A0A3-8D6E-4835-9E03-E0FF1D3E339D

P31

Q34508696-26CB0267-A5F7-4557-951B-18E59BA6306C

P356

Q34508696-9C77DE9A-AD1C-451E-9F1B-3B58DFFAC54A

P407

Q34508696-965C0B0B-9505-4E5C-8749-DDDC0767FF67

P433

Q34508696-0B4820AC-2CEA-41E7-9B02-2FD6787EBE32

P478

Q34508696-B5EC98F8-9A76-4FBD-886C-8FDE6FA93241

P577

Q34508696-B5F34F78-1361-44B6-9B1F-A7C058BC57F6

P5875

Q34508696-4E6F891C-0A6C-4520-B4C4-8D21F5C5FEB1

P698

Q34508696-B72A5772-BBE3-4330-9592-BF9D481A0A25

P356

0008-5472.CAN-06-0168

P1433

Cancer Research

P1476

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

@en

P2093

Arul M Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

Beth E Helgeson

http://www.w3.org/2001/XMLSchema#string

Daniel R Rhodes

http://www.w3.org/2001/XMLSchema#string

Diane Roulston

http://www.w3.org/2001/XMLSchema#string

John T Wei

http://www.w3.org/2001/XMLSchema#string

Lisa R Smith

http://www.w3.org/2001/XMLSchema#string

Mark A Rubin

http://www.w3.org/2001/XMLSchema#string

Rajal B Shah

http://www.w3.org/2001/XMLSchema#string

Rohit Mehra

http://www.w3.org/2001/XMLSchema#string

Scott A Tomlins

http://www.w3.org/2001/XMLSchema#string

P304

3396-3400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-06-0168

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7195197

http://www.w3.org/2001/XMLSchema#string

P698

16585160

http://www.w3.org/2001/XMLSchema#string